Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings, to discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa™ mucoadhesive product, PPP002.
Read more
Tetra Bio-Pharma Confirms Meetings With FDA
